|
Name |
Phe-Pro-Lys
|
| Molecular Formula | C20H30N4O4 | |
| IUPAC Name* |
(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
|
|
| SMILES |
C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCCCN)C(=O)O
|
|
| InChI |
InChI=1S/C20H30N4O4/c21-11-5-4-9-16(20(27)28)23-18(25)17-10-6-12-24(17)19(26)15(22)13-14-7-2-1-3-8-14/h1-3,7-8,15-17H,4-6,9-13,21-22H2,(H,23,25)(H,27,28)/t15-,16-,17-/m0/s1
|
|
| InChIKey |
ZVRJWDUPIDMHDN-ULQDDVLXSA-N
|
|
| Synonyms |
Phe-Pro-Lys; Phenylalanyl-prolyl-lysine; L-Phenylalanyl-L-prolyl-L-lysine; CHEBI:161812; (2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
|
|
| CAS | NA | |
| PubChem CID | 11153522 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 390.5 | ALogp: | -2.8 |
| HBD: | 4 | HBA: | 6 |
| Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 139.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 28 | QED Weighted: | 0.433 |
| Caco-2 Permeability: | -6.41 | MDCK Permeability: | 0.00049182 |
| Pgp-inhibitor: | 0.098 | Pgp-substrate: | 0.009 |
| Human Intestinal Absorption (HIA): | 0.966 | 20% Bioavailability (F20%): | 0.013 |
| 30% Bioavailability (F30%): | 0.253 |
| Blood-Brain-Barrier Penetration (BBB): | 0.204 | Plasma Protein Binding (PPB): | 8.18% |
| Volume Distribution (VD): | 0.327 | Fu: | 84.04% |
| CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.039 |
| CYP2C19-inhibitor: | 0.042 | CYP2C19-substrate: | 0.059 |
| CYP2C9-inhibitor: | 0.025 | CYP2C9-substrate: | 0.145 |
| CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.217 |
| CYP3A4-inhibitor: | 0.034 | CYP3A4-substrate: | 0.056 |
| Clearance (CL): | 3.155 | Half-life (T1/2): | 0.849 |
| hERG Blockers: | 0.047 | Human Hepatotoxicity (H-HT): | 0.414 |
| Drug-inuced Liver Injury (DILI): | 0.017 | AMES Toxicity: | 0.009 |
| Rat Oral Acute Toxicity: | 0.134 | Maximum Recommended Daily Dose: | 0.094 |
| Skin Sensitization: | 0.136 | Carcinogencity: | 0.04 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.019 |
| Respiratory Toxicity: | 0.334 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001906 | ![]() |
0.617 | D07HGR | ![]() |
0.674 | ||
| ENC001904 | ![]() |
0.402 | D0X5SJ | ![]() |
0.598 | ||
| ENC000717 | ![]() |
0.400 | D0N5HJ | ![]() |
0.547 | ||
| ENC003576 | ![]() |
0.389 | D00SEB | ![]() |
0.500 | ||
| ENC000130 | ![]() |
0.388 | D00DEF | ![]() |
0.489 | ||
| ENC000810 | ![]() |
0.369 | D06PSS | ![]() |
0.420 | ||
| ENC000918 | ![]() |
0.362 | D0R1CR | ![]() |
0.388 | ||
| ENC000749 | ![]() |
0.333 | D01STB | ![]() |
0.385 | ||
| ENC002436 | ![]() |
0.327 | D0RA5Q | ![]() |
0.384 | ||
| ENC004716 | ![]() |
0.315 | D0M5OC | ![]() |
0.375 | ||